Inhibition of osteosarcoma-induced thermal hyperalgesia in mice by the orally active dual enkephalinase inhibitor PL37. Potentiation by gabapentin.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  European Journal of Pharmacology

• Publication date

  2008-10-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejphar.2008.07.043PMID 18692494
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Use of preproenkephalin knockout mice and selective inhibitors of enkephalinases to investigate the role of enkephalins in various behaviours

  2008cited by this paper
• RB101-mediated protection of endogenous opioids: potential therapeutic utility?

  2007cited by this paper
• Chemical Interactions between Fibrosarcoma Cancer Cells and Sensory Neurons Contribute to Cancer Pain

  2007cited by this paper
• Pharmacological evaluation of opioid and non-opioid analgesics in a murine bone cancer model of pain.

  2007cited by this paper
• Protection of endogenous enkephalin catabolism as natural approach to novel analgesic and antidepressant drugs

  2007cited by this paper
• Involvement of nitric oxide in the inhibition of bone cancer-induced hyperalgesia through the activation of peripheral opioid receptors in mice.

  2007cited by this paper
• Possible activation of the NO-cyclic GMP-protein kinase G-K+ channels pathway by gabapentin on the formalin test.

  2006cited by this paper
• Pain control by CXCR2 ligands through Ca2+ ‐regulated release of opioid peptides from polymorphonuclear cells

  2006cited by this paper
• Endogenous beta-endorphin induces thermal analgesia at the initial stages of a murine osteosarcoma.

  2006cited by this paper
• Analgesic effects of loperamide in bone cancer pain in mice.

  2005cited by this paper
• Tumor-induced injury of primary afferent sensory nerve fibers in bone cancer pain.

  2005influential reference
• Effects of the local administration of selective μ-, δ-and κ-opioid receptor agonists on osteosarcoma-induced hyperalgesia

  2005cited by this paper
• Peripheral versus Central Antinociceptive Actions of 6-Amino Acid-Substituted Derivatives of 14-O-Methyloxymorphone in Acute and Inflammatory Pain in the Rat

  2005cited by this paper
• Gabapentin Normalizes Spinal Neuronal Responses That Correlate with Behavior in a Rat Model of Cancer-induced Bone Pain

  2005cited by this paper
• Effects of the local administration of selective mu-, delta-and kappa-opioid receptor agonists on osteosarcoma-induced hyperalgesia.

  2005cited by this paper
• Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group.

  2004cited by this paper
• Tumor implantation in mouse humerus evokes movement‐related hyperalgesia exceeding that evoked by intramuscular carrageenan

  2003cited by this paper
• Peripheral opioids act as analgesics in bone cancer pain in mice

  2003influential reference
• Suppression by gabapentin of pain-related mechano-responses in mice given orthotopic tumor inoculation.

  2003cited by this paper
• Potent analgesic effects of anticonvulsants on peripheral thermal nociception in rats

  2003cited by this paper
• Initial thermal heat hypoalgesia and delayed hyperalgesia in a murine model of bone cancer pain.

  2003influential reference
• The interaction index: a measure of drug synergism

  2002influential reference
• Unilateral hot plate test: a simple and sensitive method for detecting central and peripheral hyperalgesia in mice.

  2002cited by this paper
• Drug synergism: its detection and applications.

  2001influential reference
• Met-enkephalin is preferentially transported into the peripheral processes of primary afferent fibres in both control and HSV1-driven proenkephalin A overexpressing rats.

  2001cited by this paper
• Enhancement of the effects of a complete inhibitor of enkephalin‐catabolizing enzymes, RB 101, by a cholecystokinin‐B receptor antagonist in diabetic rats

  2001cited by this paper
• Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons.

  2000cited by this paper
• Novel approaches to targeting neuropeptide systems.

  2000cited by this paper
• Crosstalk between nervous and immune systems through the animal kingdom: focus on opioids

  2000cited by this paper
• The effects of RB101, a mixed inhibitor of enkephalin-catabolizing enzymes, on carrageenin-induced spinal c-Fos expression are completely blocked by beta-funaltrexamine, a selective mu-opioid receptor antagonist.

  1999cited by this paper
• Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain.

  1999cited by this paper
• Neurochemical and Cellular Reorganization of the Spinal Cord in a Murine Model of Bone Cancer Pain

  1999cited by this paper
• The effects of RB101, a mixed inhibitor of enkephalin-catabolizing enzymes, on carrageenin-induced spinal c-Fos expression are completely blocked by β-funaltrexamine, a selective μ-opioid receptor antagonist

  1999influential reference
• Attenuation of formalin‐induced nociceptive behaviors following local peripheral injection of gabapentin

  1998cited by this paper
• Gabapentin (neurontin) and S‐(+)‐3‐isobutylgaba represent a novel class of selective antihyperalgesic agents

  1997cited by this paper
• The Dual Peptidase Inhibitor RB101 Induces a Long‐Lasting Increase in the Extracellular Level of Met‐Enkephalin‐Like Material in the Nucleus Accumbens of Freely Moving Rats

  1996cited by this paper
• Antinociceptive effect of systemic kelatorphan, in mononeuropathic rats, involves different opioid receptor types.

  1994cited by this paper
• Antinociceptive response induced by mixed inhibitors of enkephalin catabolism in peripheral inflammation

  1994cited by this paper
• Antinociceptive effect of systemic PC 12, a prodrug mixed inhibitor of enkephalin-degrading enzymes, in normal and arthritic rats.

  1993cited by this paper
• Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology.

  1993cited by this paper
• Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats.

  1992cited by this paper
• Evidence that endogenous enkephalins produce delta-opiate receptor mediated neuronal inhibitions in rat dorsal horn.

  1986cited by this paper

• A comprehensive review of the literature on CD10: its function, clinical application, and prospects

  2024cites this paper
• Synergistic effect of combining dual enkephalinase inhibitor PL37 and sumatriptan in a preclinical model of migraine

  2024cites this paper
• Experiences and reflections about behavioral pain assays in laboratory animals.

  2023cites this paper
• Novel Opioids in the Setting of Acute Postoperative Pain: A Narrative Review

  2023cites this paper
• Efficacy of dual enkephalinase inhibition in a preclinical migraine model is mediated by activation of peripheral delta opioid receptors

  2023cites this paper
• The inhibition of enkephalin catabolism by dual enkephalinase inhibitor: A novel possible therapeutic approach for opioid use disorders

  2021cites this paper
• Neprilysin expression and functions in development, ageing and disease

  2020cites this paper
• Replacement of current opioid drugs focusing on MOR-related strategies.

  2020cites this paper
• Inhibitors of neuropeptide peptidases engaged in pain and drug dependence.

  2020cites this paper
• Optimization and In Vivo Profiling of a Refined Rat Model of Walker 256 Breast Cancer Cell-Induced Bone Pain Using Behavioral, Radiological, Histological, Immunohistochemical and Pharmacological Methods

  2017cites this paper
• Synergistic combinations of the dual enkephalinase inhibitor PL265 given orally with various analgesic compounds acting on different targets, in a murine model of cancer-induced bone pain

  2017cites this paper
• ynergistic combinations of the dual enkephalinase inhibitor PL 265 iven orally with various analgesic compounds acting on different argets , in a murine model of cancer-induced bone pain

  2016cites this paper
• Contribution of Delta-Opioid Receptors to Pathophysiological Events Explored by Endogenous Enkephalins.

  2016cites this paper
• Long-lasting oral analgesic effects of N-protected aminophosphinic dual ENKephalinase inhibitors (DENKIs) in peripherally controlled pain

  2015cites this paper
• Modulation of disulfide dual ENKephalinase inhibitors (DENKIs) activity by a transient N-protection for pain alleviation by oral route.

  2015cites this paper
• New orally active dual enkephalinase inhibitors (DENKIs) for central and peripheral pain treatment.

  2014cites this paper
• [New painkillers inhibiting the physiological breakdown of endogenous opioids].

  2012cites this paper
• [More myelin is not necessarily good].

  2012cites this paper
• Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain

  2012cites this paper
• Current world literature.

  2010cites this paper
• Exaltation du contrôle de la douleur par les enképhalines endogènes par inhibition de leur inactivation enzymatique, une nouvelle approche vers des analgésiques physiologiques

  2009cites this paper
• nvolvement of enkephalins in the inhibition of osteosarcoma-induced thermal yperalgesia evoked by the blockade of peripheral P 2 X 3 receptors

  2009cites this paper
• Involvement of enkephalins in the inhibition of osteosarcoma-induced thermal hyperalgesia evoked by the blockade of peripheral P2X3 receptors.

  2009cites this paper
• Endogenous opiates and behavior: 2008.

  2009cites this paper